April 21, 2022
Execution of a license agreement on an exclusive marketing right in Japan of the first donepezil transdermal therapeutic system in Japan
Teikoku Seiyaku Co., Ltd. (Head office: Higashikagawa City, Kagawa, Japan) and Kowa Company, Ltd. (Head office: Nagoya City, Aichi, Japan) have reached a license agreement on an exclusive marketing right in Japan of the first donepezil transdermal therapeutic system (tape formulation) in Japan as a candidate of a treatment of dementia of the Alzheimer type.
This tape formulation is the first transdermal therapeutic system contains donepezil as an active pharmaceutical ingredient in Japan. Donepezil suppresses progression of cognitive decline associated with dementia of the Alzheimer type by activation of cholinergic neurons through elevation of brain acetylcholine level by inhibiting acetylcholine esterase, an acetylcholine degrading enzyme contained in brain-nerve system.
Teikoku Seiyaku have submitted New Drug Application in Japan to the Ministry of Health, Labour and Welfare in January 2022 and Kowa will exclusively market this tape formulation in Japan after obtaining the manufacturing and marketing approval under this license agreement.
Teikoku Seiyaku and Kowa would like to contribute to more patients, care givers and healthcare providers to provide this tape formulation as a new treatment option for dementia of the Alzheimer type.
For further information, please contact:
Teikoku Seiyaku Co., Ltd. General Affairs Department